drugset / Trial / NCT06951425
An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors
Phase 0
Not yet recruiting
24 enrolled
Shanghai Tongji Hospital, Tongji University School of Medicine
ThinkingBiomed · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase l, Open-Label, Dose-escalation Study to Evaluate the Safety, Tolerabilityand Antitumor Activity of TH027 CAR-T Cell lnjection (TH-CART-027) in Subjects With Relapsed or Refractory Solid Tumors.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TH-CART-027 | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | TH-CART-027 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | TH-CART-027 | Cell therapy | 3e+06 cells/kg | Intravenous |